Canadian non-profit Conscience has launched a national initiative to accelerate drug discovery using artificial intelligence. The AI-Driven Medicines program will fund computational and digital tools aimed at improving research efficiency and advancing accessible therapies. Eligible projects can receive up to $1 million, with higher support levels for small businesses.
The initiative targets areas including discovery science, manufacturing optimization, and clinical trials. Officials say the program supports open collaboration and responsible AI use. Federal minister Evan Solomon endorsed the effort, highlighting its potential to improve affordability and public health outcomes while strengthening Canada’s position in life sciences innovation.
Want to know more? Check out the source code here.